Home Top Movers Companies Concepts

Market

Top Movers
Companies
Concepts

SEC Filings

AI Filing Analysis
Financial Reports
Current Reports
IPO Filings

Ownership

Institutional Holdings
Insider Trading

About

Data updates every 5 min
SEC EDGAR Source

© 2025–2026 StockGist|Information only, not investment advice

SCHEDULE 13G/A - 4D Molecular Therapeutics, Inc. | StockGist | StockGist

Companies
FDMT
SCHEDULE 13G/A

Home Top Movers Companies Concepts

Home Filings FDMTSCHEDULE 13G/A

SCHEDULE 13G/A

Beneficial Ownership

Amendment

4D Molecular Therapeutics, Inc.

Filed Feb 17, 2026

Accepted Feb 16, 2026, 7:00 PM ET

CIK 0001650648

View on SEC.gov Company Profile

Beneficial Ownership Report

Passive Investment

Reporting Person

4D Molecular Therapeutics, Inc.

Person Type

CO

CUSIP: 35104E100

Amendment History

5 filings

SCHEDULE 13G
Original
Feb 17, 20260001274173-26-000069
SCHEDULE 13G/A
Amendment 1
Feb 17, 20260001346824-26-000029
SCHEDULE 13G/A
Amendment 2
Viewing
Feb 17, 20260001388325-26-000011
SCHEDULE 13G/A
Amendment 3
Feb 17, 20260000921895-26-000459
SCHEDULE 13G/A
Amendment 4
Latest
Mar 26, 20260000102909-26-000363

Recent Filings

4D Molecular Therapeutics, Inc.5 days ago

4D Molecular Therapeutics, Inc.1 weeks ago

4D Molecular Therapeutics, Inc.1 months ago

4D Molecular Therapeutics, Inc.1 months ago

4D Molecular Therapeutics, Inc.1 months ago

Data Sources

Original SEC Filing SEC EDGAR Company Page

Market

Top Movers
Companies
Concepts

SEC Filings

AI Filing Analysis
Financial Reports
Current Reports
IPO Filings

Ownership

Institutional Holdings
Insider Trading

About

Data updates every 5 min
SEC EDGAR Source

© 2025–2026 StockGist|Information only, not investment advice